A Health Leaders Media story noted “At Mount Sinai Health System in New York, a combination of personalized medicine, natural language processing, and clever integration with electronic health record software is allowing clinicians to adjust medication selection and dosages based on patients’ genomic differences.”
“Personalized medicine is one of those technology topics that perpetually comes up in conversations about The Next Big Thing. Think combining genomics data with population health, throw in some predictive analytics, and you’ve got the basic idea.”
Click here to read the full Health Leaders Media article “Personalized Medicine Meets EHR Integration at Mount Sinai” by Scott Mace.
Doctor, Did You Wash Your Hands? ™ provides information to consumers on understanding, managing and navigating health care options.
Jonathan M. Metsch, Dr.P.H., is Clinical Professor, Preventive Medicine, Icahn School of Medicine at Mount Sinai; and Adjunct Professor, Baruch College ( C.U.N.Y.), Rutgers School of Public Health, and Rutgers School of Public Affairs and Administration.
This blog shares general information about understanding and navigating the health care system. For specific medical advice about your own problems, issues and options talk to your personal physician.
This year’s program will feature a number of exciting speakers, exhibitors, and demonstrations exploring the expanding interface between engineering and medicine—and how it is transforming all aspects of health care.
Topics include: breakthroughs in material science, nanotechnology, and imaging; genomics and personalized medicine; transformative technologies, including apps, software, and mobile technologies; and engineering to improve global health.
More than 300 employees and patients of the Mount Sinai Health System recently gathered in the Guggenheim Atrium to celebrate the 30,000th participant in the BioMe Biobank. The Biobank collects de-identified DNA and plasma used for a variety of research purposes from consenting patients.
In February, CBS This Morning had a segment on Mount Sinai’s novel use of fruit flies to screen for personalized cancer drugs. Ross Cagan, PhD, Associate Dean of the Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, discussed how his laboratory replicates a patient’s tumor and implants it in a fruit fly. Then his team tests an arsenal of 840 drugs—all approved by the U.S. Food and Drug Administration for other uses—to see if they shrink the tumor.
Vast amounts of data from genomic sequencing and electronic health records (EHRs) have the potential to radically improve the health of individual patients, but first, institutions must learn how to manage the data, and adopt uniform standards that allow them to share it.
This discussion took center stage at a Working Summit on Big Data hosted by The Atlantic in partnership with the Mount Sinai Health System on Wednesday, October 23, at The New York Palace Hotel. At a roundtable discussion, 24 policymakers, entrepreneurs, and health care leaders shared their thoughts and experiences in harnessing petabytes of data for use in improving human health.
Personalized Medicine is a rapidly evolving approach to patient care that incorporates an individual’s genetic information into a customized prevention or treatment plan. Mapping a person’s total genetic makeup or whole genome sequencing has created mountains of data about variations in our human genetic code. As this experience has grown, some of these variations have been linked to risks for certain diseases, or in some cases the likelihood that a person will respond to a particular treatment. Individuals may now submit a DNA sample and obtain their genetic sequence with accompanying risk association analysis for a few hundred dollars. Can this technology however be harnessed to drive better outcomes for patients diagnosed with cancer? Many clinicians and scientists argue that we are not there yet.